Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus

Phase 1AT-587Positive

AI Analysis

Summary

Atea Pharmaceuticals initiated a first-in-human Phase 1 clinical trial of AT-587 to evaluate safety, tolerability, and pharmacokinetics in healthy volunteers for the treatment of Hepatitis E Virus.

Clinical Trial Data

Phase

Phase 1

Importance:5/10

Sentiment:

0.30

Phase 1Clinical TrialHepatitis EFirst-in-HumanSafetyTolerabilityPharmacokinetics

Related Companies

$AVIR

Read the original article

Published by GlobeNewswire Pharma on July 14, 2026 11:00 AM

Read Original